ADC Therapeutics SA Proceeds From Borrowings Classified As Financing Activities
ADC Therapeutics SA (ADCT) reported Proceeds From Borrowings Classified As Financing Activities of $0 for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-15.
Discontinued › Cash Flow › Financing Activities
ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities · last filed 2023-03-15
- ADC Therapeutics SA proceeds from borrowings classified as financing activities for the quarter ending 2022-12-31 was $0.00.
- ADC Therapeutics SA proceeds from borrowings classified as financing activities for the quarter ending 2022-09-30 was $0.00.
- ADC Therapeutics SA proceeds from borrowings classified as financing activities for the quarter ending 2021-12-31 was $0.00.
- ADC Therapeutics SA proceeds from borrowings classified as financing activities for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
| Period end | Proceeds From Borrowings Classified As Financing Activities 3 month | Proceeds From Borrowings Classified As Financing Activities 6 month | Proceeds From Borrowings Classified As Financing Activities 9 month | Proceeds From Borrowings Classified As Financing Activities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 20-F · filed 2023-03-15 | |
| 2022-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $0.00 6-K · filed 2022-11-08 | ||
| 2022-06-30 | $0.00 6-K · filed 2022-08-09 | |||
| 2021-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $49.59M 20-F · filed 2023-03-15 | |
| 2021-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $49.59M 6-K · filed 2022-11-08 | ||
| 2021-06-30 | $49.59M 6-K · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $2.00K derived: sum of 2 quarters · filed 2023-03-15 | $62.90M 20-F · filed 2023-03-15 | |
| 2020-09-30 | $2.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $62.90M 6-K · filed 2021-11-02 | ||
| 2020-06-30 | $62.90M 6-K · filed 2021-08-03 | |||
| 2019-12-31 | $0.00 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $0.00 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |